Skip to main content

Journals in Pharmacology

Elsevier's Pharmacology collection studies how drugs interact with biological systems to improve health and treat disease. It covers pharmacodynamics, exploring drug effects on biology, and pharmacokinetics, studying how the body affects drugs. Branches like Pharmacogenetics. Essential for pharmacologists, this collection offers invaluable insights into drug interactions, efficacy, and safety, crucial for advancing drug development and improving patient outcomes.

  • Contemporary Clinical Trials

    • ISSN: 1551-7144
    Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers not exceeding 4,000 words, short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/comment... on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.The following topics are covered in the journal:Unconvention... design features of specific trials and their rationalePreliminary or full results of clinical trials with unconventional design featuresStatistical methods for all aspects of clinical trialsMethodologies for clinical trial operations including trial management and optimization; patient recruitment and retention; and trial quality monitoring and assessmentData management methodologies including data collection; database maintenance; data quality assurance; safety monitoring and risk management; and patient registriesRegulatory requirements and their impact on clinical trialsEthical and legal considerations in clinical trialsRisk-benefit, cost-effectiveness and decision analyses in clinical trialsContemporary Clinical Trials is unique in that it is outside the confines of disease specifications, and it strives to adapt and grow with an expanding clinical trials landscape as the needs of clinical research evolve in today's dynamic healthcare environment.Having taken upon the important role as a platform for knowledge exchange between experts in different disciplines related to clinical trials, the ultimate goal of Contemporary Clinical Trials is to advance this field of research for the benefit of patients.Authors are also welcome to submit to the journal's open access companion title, Contemporary Clinical Trials Communications.
  • Cellular Signalling

    • ISSN: 0898-6568
    Cellular Signalling publishes original research describing fundamental and clinical findings on the mechanisms, actions and structural components of cellular signalling systems in vitro and in vivo.Cellular Signalling aims at full length research papers defining signalling systems ranging from microorganisms to cells, tissues and higher organisms.Cellular Signalling strives to offer a fair and fast peer-review process with a single round of revisions. Reviews are by invitation-only. Short Reports are not accepted.
  • Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics

    • ISSN: 1744-117X
    Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology.Part D: Genomics and Proteomics (CBPD), focuses on “omics” approaches to physiology, including comparative and functional genomics, metagenomics, transcriptomics, proteomics, metabolomics, and lipidomics. Most studies employ “omics” and/or system biology to test specific hypotheses about molecular and biochemical mechanisms underlying physiological responses to the environment. We encourage papers that address fundamental questions in comparative physiology and biochemistry rather than studies with a focus that is purely technical, methodological or descriptive in nature.All four CBP journals support and follow the editorial direction from all the major societies in the field:Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB)American Physiological Society (APS)Canadian Society of Zoologists (CSZ)Deutsche Zoologische Gesellschaft (DZG)European Society of Comparative Physiology and Biochemistry (ESCPB)Japanese Society for Comparative Physiology and Biochemistry (JSCPB)South American Society for Comparative Physiology and Biochemistry (SASCPB)Societe de Physiologie (SDP)Society for Experimental Biology (SEB)Society for Integrative & Comparative Biology (SICB)CBP journals are focused on promoting the authors and the work published in the journal:All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field.Availability: contact the Editor-in-Chief for any questions you may have.The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library.Publication is free to authors (no color or page charges).Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here.Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect.Please click here for more information on more general author services.Other CBP journals Part A (CBPA): Molecular & Integrative Physiology Part B (CBPB): Biochemistry & Molecular Biology Part C (CBPC): Toxicology & Pharmacology
  • Free Radical Biology & Medicine

    • ISSN: 0891-5849
    The journal Free Radical Biology and Medicine is the premier forum for publishing ground-breaking research in the redox biology of both health and disease. We focus on signal transduction and redox signaling; oxidative stress; reductive stress; redox stress; nitrosative stress; aging and age-related diseases; redox biology in skeletal and cardiac muscle, exercise science, and sports medicine; metabolic regulation and metabolic diseases; mitochondrial function and signaling; homeostatic mechanisms and adaptive responses; redox chemistry and mechanisms; materials and nanomaterials; non-thermal plasmas; microorganisms, fungi, plants, insects, animals, and humans; and antioxidant enzymes, pathways, and networks.The journal welcomes both full-length and short Research Communications, Hypothesis Papers, Reviews, Mini Reviews, Graphical Reviews, and Critical Methods Papers. Free Radical Biology and Medicine is the official journal of the Society for Redox Biology and Medicine and the Society for Free Radical Research-Europe, and affiliate journal of the International Society for Free Radical Research (SFRRI)
  • Molecular Aspects of Medicine

    • ISSN: 0098-2997
    Molecular Aspects of Medicine is a review journal for Physicians and Biomedical Scientists and an official journal of the International Union of Biochemistry and Molecular Biology. Molecular Aspects of Medicine aims to encourage the bridging of the gap between clinicians of all relevant specialities and biomedical scientists. The journal anticipates that most of the authors contributing to the series will be practising clinical scientists who will develop their own personal perspective as an extended review on the molecular aspects of a field of medicine in which they are working, addressing themselves both to the doctor who is ill-at-ease with basic science, and to the basic scientist with little awareness of the problems of clinical practice.It publishes articles on a spectrum of topics in medicine to illustrate not only the molecular insights that derive from the application of basic science, but also the variety of challenging problems that medicine is able to offer the basic scientist.Submission... on from biochemistry and molecular and cell biology to physiology, pharmacology and pathology are particularly welcomed.
  • International Immunopharmacology

    • ISSN: 1567-5769
    International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions. • Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system.• Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses. • The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc. These Backfiles include Immunopharmacology and the International Journal of Immunopharmacology .International Immunopharmacology does not accept submissions that consist primarily of bioinformatics or computational analyses of public genomic or transcriptomic databases, unless they are supported by experimental studies involving cells, organoids, or experimental animals.
  • Life Sciences

    • ISSN: 0024-3205
    Life Sciences is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. The journal emphasizes the understanding of mechanism that is relevant to all aspects of human disease and translation to patients. All articles are rigorously reviewed.The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of brief, focused reviews containing high-quality artwork and require the use of mechanistic summary diagrams.Manuscripts should present novel preclinical findings addressing questions of biological significance to human disease. Studies that fail to do so may be rejected without review. Quantitative conclusions must be based on truly quantitative methods. Life Sciences does not publish work on the actions of biological extracts of unknown chemical composition. Compounds studied must be of known chemical structure and concentration. The study must be reproducible; materials used must be available to other researchers so they can repeat the experiment. Clinical studies may be considered if they expand understanding of mechanism, but the journal does not encourage clinical trial reports.Four common reasons for rejection include: out of scope (the manuscript does not conform to the goal of identification of mechanisms related to therapy for human disease); too preliminary (manuscript is based on a limited amount of experimental data diminishing significance); lack of novelty (manuscript is well done but does not address a significant question); unidentified structure (actions of biological extracts of unknown chemical composition).
  • Neuropharmacology

    • ISSN: 0028-3908
    Neuropharmacology publishes high quality, original research within the discipline of neuroscience. The emphasis of Neuropharmacology is on the study and understanding of the actions of known exogenous and endogenous chemical agents on neurobiological processes in the mammalian nervous system. Work with non-mammalian and invertebrate species may be considered in exceptional circumstances. The journal does not usually accept clinical research, although neuropharmacological studies in humans may be considered on the condition that they provide novel insight into either the actions of drugs and/or neurobiological mechanisms. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Similarly, manuscripts describing the use of natural products will only be considered if the active ingredient is known and disclosed.The journal publishes Special Issues in which leading experts are invited to serve as Guest Editors to compile a collection of reviews, and occasionally original articles, around a particular topical theme in neuroscience research. The list of recent Special Issues can be found here. Suggestions for Special Issues can be made directly to the Editor-in-Chief.Neur... also publishes topical narrative reviews on subjects within its remit. These reviews are commissioned by the Editorial Team or arise after correspondence with potential authors. Unsolicited reviews will be considered, but authors are encouraged to contact the Editor-in-Chief of their intention to submit a review. Potential review authors should clearly indicate in the cover letter their expertise in the area, the timeliness of the topic, and how the review differs from, and adds to, recent published reviews on related topics. Authors are expected to have an established experimental track record in the topic of the review, and should provide full citations, including URLs/DOIs, of recent experimental papers in peer-reviewed journals relevant to the topic of the review in their cover letter. In the absence of an experimental track record, authors should provide a justification for why they believe they are the right persons to author this review article at this point in time. The absence of any such evidence of relevant experimental expertise or an explanation of author appropriateness will result in the return of the manuscript to the authors. On the basis of the case made by authors, potential overlap with planned Neuropharmacology content, and discussions with the Editorial Team, the Editor-in-Chief will provide authors with a prompt decision regarding the proposed review. Systematic reviews, meta- or bibliographic analyses will not be considered unless they are a necessary part of a Special Issue and conducted by experts in the field, and even then only under exceptional circumstances and at the discretion of the Editor-in-Chief.
  • Schizophrenia Research

    • ISSN: 0920-9964
    An International Multidisciplinary Journal of the Schizophrenia International Research SocietyAs an official journal of the Schizophrenia International Research Society (SIRS) Schizophrenia Research is THE journal of choice for international researchers and clinicians to share their work with the global schizophrenia research community. More than 6000 institutes have online or print (or both) access to this journal - the largest specialist journal in the field, with the largest readership!Schizophr... Research's time to first decision is as fast as 6 weeks and its publishing speed is as fast as 4 weeks until online publication (corrected proof/Article in Press) after acceptance and 14 weeks from acceptance until publication in a printed issue.The journal publishes novel papers that really contribute to understanding the biology and treatment of schizophrenic disorders; Schizophrenia Research brings together biological, clinical and psychological research in order to stimulate the synthesis of findings from all disciplines involved in improving patient outcomes in schizophrenia.Manusc... with a focus on cognition in schizophrenia can be submitted to the journal's open access companion title, Schizophrenia Research: Cognition.
  • Journal of Controlled Release

    • ISSN: 0168-3659
    The Journal of Controlled Release (JCR) is the Official Journal of the Controlled Release Society, and of the Japan Society of Drug Delivery System.It publishes high-quality research articles in the broad field of delivery science and technology. This includes drug delivery systems and all aspects of formulations, such as physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development in the disciplines of pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.Manuscrip... that advance fundamental understanding of principles and/or demonstrate advantages of novel technologies in safety and efficacy over current clinical standards will be given priority.